Sanofi-Aventis (SNY) On the Prowl For A Mega-Deal In the U.S.?
More News related to AGN
- Spectrum Pharma (SPPI) To Collaborate with Nippon Kayaku to Develop and Commercialize Apaziquone in Asia
- The Lowe Law Firm Files Suit over Alleged Botox Overdose
- Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
- Allergan (AGN) Posts Q3 EPS of $1.13, Topping Street; Guides FY09
- Don't Miss Out! The Registration Period for the 2010 IR Global Rankings Ends TOMORROW!
More News related to AMGN
- Amgen (AMGN) Announces Cancer Survival Results when Faced with Vectibix in Combination with FOLFOX
- Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
- Call for Applications: The Amgen Award for Science Teaching Excellence
- Trading Outlook for Avanir Pharmaceuticals Inc. Issued by InvestorSoup.com
- Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
More News related to BIIB
- Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Jefferies & Co Upgrades Biogen Idec (BIIB) to Buy
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Trading Outlook for Incyte Corp. Issued by StockPreacher.com
According to reports the Wall Street Journal's Deal Journal, Sanofi-Aventis (NYSE: SNY) is on the prowl for a mega-deal in the U.S, citing reports in French business newspaper Les Echos.
Deal Journal said one obvious takeover target is Bristol-Myers Squibb (NYSE: BMY), since the two companies already have an existing partnership developing blood clot drug Plavix. Amgen (Nasdaq: AMGN) is seen as another possible takeover candidate.
European bankers said a deal to acquire Amgen could jeopardize Sanofi’s investment-grade credit rating.
Other more likely takeover targets include botox-maker Allergan (NYSE: AGN) or biotech company Biogen Idec (Nasdaq: BIIB), where activist investor Carl Icahn just won two board seats.
Link to WSJ Deal Journal Article
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Insiders' BlogRumors
Stocks Mentioned
+0.27
-0.79Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
